Phase II Clinical Research Expand the Applications of Ipilimumab and Nivolumab in Prostate Cancer Patients

Release Date: 21-Nov-2020

The clinical outcome of the phase II led by the researchers from the Texas University have concluded that the combination of the drug ipilimumab and nivolumab could generate potential result in the patients suffering from metastatic castration-resistant prostate cancer. All the enrolled patients in the clinical research study has overall response rate 25%, overall survival of 19 months (patients without chemotherapy treatment) and in the group who had received chemotherapy has overall response rate 10% and media overall survival 15.2 months. Among all, 4 patients received complete response.

Now, the primary aim of the researchers involved in the clinical research study is to identify the doses that could reduce the level of toxicities related with the combination. All the results that were found in the respective clinical research study suggested that the combination identified by the researchers is very useful in treating the patients who haven’t respond to any of the therapies available. The evaluation of the safety profile of the combination is estimated to be re-define the entire cancer therapeutics market.

The combination of the drugs decided for the cancer led to the arrival of activated T cells at the site of the tumor. There was a huge percentage of the patients enrolled in the study that received benefit from the tumor. The further plan of the clinical research study is to evaluate the combination in a big group of patients i.e. approximately 400. It is estimated that future plans of the clinical research study will improve the effectiveness of the combination and will minimize the toxicities that are related with the therapy. The future generated data from the trial is estimated to transform the unstructured market scenario for the cancer therapeutics market and thus providing enormous amount of healthcare benefits to the cancer patients across the globe.